Featured Jobs
|
Director Clinical Informatics Amerigroup Corporation |
|
|
AVP Provider Network Pricing Amerigroup Corporation |
|
|
SENIOR HEALTHCARE ANALYST Boston Health Economics, Inc. |
|
|
|
News
- Key Speakers added for DIA 2012: Collaborate to Innovate meeting
- Health outcomes liaisons in high demand
- Can Big Pharma cure cancer in emerging markets?
- Extending the Life Cycle of a Mature Brand in an Emerging Market
- Workforce Health and Productivity Report
- India's pharma success story
- What are the challenges working in the Asian-Pacific marketplace?
- Bayer's Cancer Cure?
- New market research on industry efforts to enhance the patient experience and satisfaction of care
- Should cost-effectiveness evidence be relevant in Medicare decision making?
- How to overcome mounting European pharma debt
- Will there be convergence between the UK's NICE and Germany's IQWiG?
- New Report Available - Market and Product Forecasts: Targeted Cancer Therapies
- How will German health reform impact pharma market access in 2012?
- Can competition help the integration of care?
- Trends in PRO: Interview with Dr. Arthur Stone
- The gamification of health care
- Proportion of Days Covered vs. Medication Possession Ratio
- Can you guess PharmExecs brand of the year?
- The three P’s of effectiveness research: PCORI, Priorities, and Politics
- How do price changes affect Medicare beneficiaries?
- Are patients' perspectives important from the beginning of clinical trials?
- Another prostate cancer pill bites the dust
- What's next for IBM's Watson?
- Integrating scientific and real-world evidence within and beyond the drug development process
- New Journal Launched - The Journal of Comparative Effectiveness Research
- NPC selects five research projects related to CER for funding in 2012
- "Big Brother" looms in FDA lawsuit
- Are you responding to the PCORI RFI due February 17, 2012?
- Should Patents on Pharmaceuticals Be Extended to Encourage Innovation?
- Call for proposals: The Academy of Managed Care Pharmacy 2012 Educational Conference
- Gouge-fest. What do overpriced pharmaceuticals and textbooks have in common?
- Study participants needed to uncover strategies and tactics to improve patient adherence
- Does healthcare reform in France and Germany create market access barriers?
- How have NICE's HTA processes affected speed of access to new treatments?
- Different analytical approaches....different answers
- What are your thoughts about IBI's new Intervention Bank?
- Will you do this for your next medical education marketing message?
- How do you determine the economic benefits of vaccination in an increasing global world economy?
- Systematic Review of Comparative Effectiveness Data for Oncology Orphan Drugs
- What is the heart of a successful patient adherence program?
- Where to begin risk assessment? Begin at the end.
- Pharma and biotech boosting investment in medical affairs worldwide
- Embracing mobile health technology. Is our paradigm shifting?
- Germany's IQWiG sees added benefits for Incivo
- The Big Pharma Recession Report
- Nominations being sought for 7th Annual Strategic Patient Adherence Awards
- Institute of Clinical Research offers courses on medical device clinical trials and marketing.
- Why is pharma scared to innovate?
- PCORI Draft: National Priorities for Research and Research Agenda
- Public comments sought. What do you think about the PCORI National Priorities for Research draft?
- Is There a Role for Pharmacoeconomics in Developing Countries?
- Interesting flow chart summary of new FDA guidance
- ISPOR 5th Asia-Pacific Conference
- Video: Dr. Art Kaplan speaks on communication challenges for patients
- Patient Reported Outcomes. What can be gained from patient communication?
- Incremental Progress for Oncology in 2011
- The future of the Indian pharmaceutical market
- NICE’s Social Value Judgments about Equity in Health and Health Care
- CER Gaining Importance
- New descriptive analysis of more than 22,000 Cochrane meta-analyses
- Has the recession caused US citizens to forgo healthcare?
- Check out this suggested reading list for CER
- What's in it for ACO early adopters?
- Doctors on the take? Medical conflicts of interest.
- What is Encyclopedia: Patient-Reported Outcomes
- Modeling Health-Related Quality of Life over Time
- Research and Markets: Pharmacoeconomic Analysis in R&D Decision Making: An In-Depth Report
- Ethical and scientific questions surround HPV vaacinations
- Concerns surround New Outcomes Research Institute
- YouTube Video: Reimagining pharmaceutical innovation
- Read the Database of Instruments for Resource Newsletter (DIRUM)
- Novartis ax to fall….mostly on its U.S. sales team
- Blog: Asymmetry in the Ability to Communicate CER Findings: An Interview With Dr. Tevi Troy
- Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov
- Blog: Expanding Our Real-World Evidence Capabilities
- The Fate of Health Care Reform — What to Expect in 2012
- The rise of the patient and social media
- How to calculate the costs of R&D? Which methodology do you subscribe to?
- NICE snubs prostate cancer treatment
- The frenzy of medical device deals in 2011 looks to continue
- TIRF REMS Access Program receives FDA approval
- Value in Health Regional Issues Journal
- "He likes me. He really likes me."
- A Happier New Year for EuroPharma?
- Generic drug prices around Europe. Does competition matter?
- The importance of the patient perspective
- Is Bayer's Xarelto cost-effective? NICE doesn't think so…at least not yet.
- Romanian Pharmaceutical Market Grows 6.4% in 2011. Is the increase real?
- 200th Anniversary Article: A Reader’s Guide to 200 Years of the New England Journal of Medicine
- Pharma upheaval in 2011 leads to layoffs
- How should Pharma navigate the ever-changing regulations in the emerging Asian marketplace?
- Archimedes report
- National Pharmaceutical Council Expands Policy and Research Staff
- Does unpublished clinical trial data cause patient harm and increase costs?
- Podcast: CER Interview with Dan Ollendorf
- Health Reform Law charges $1/year to insurers to pay for CER studies. Is it enough?
- 2012 Pharma Pipeline Report from PharmExec.Com. Will a few blockbusters be enough?
- Are French public health experts being gagged?
- Danish Pharma agrees three-year cap on drug prices
- 6 Big HealthTech Ideas That Will Change Medicine In 2012
- ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems
- Global pharmaceutical market outlook: 2015
- Forecasting Pharma's Future
- Insights from the C-Suite: Specialty Pharma, by Taren Grom, editor
- Key to finding a new job is knowing where to look
- Up to two-thirds of NHS funding requests for cancer drugs that extend life ‘are turned down‘ in Wale
- Looking back at health IT (and more) in 2011
- Hospitals are making room for alternative therapies
- Mac’s Dr. Guyatt to enter Order of Canada
- Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
- The 'S' Word in Healthcare Reform
- Pharm Exec's 2012 Pipeline Report
- The Case of Pakistan's Private Health Expenditure
- The failure of torcetrapib, and the fallacy of reductionist science in pharma R&D.
- The Irrelevance of the Broccoli Argument against the Insurance Mandate
- FDA looks to improve the representation of women in device studies
- Ex-EU drug watchdog head's consulting gig scrutinized
- Pfizer and GSK boost pneumonia vaccine price cuts for developing world
- Nominations Open for Members of the New England CEPAC
- EMA expecting 10% more scientific advice requests in 2012
- Poland: New price negotiations for RX drugs
- Pricing Case Study from Consumer Goods: Beam Global Takes on Price Improvement
- Health Plans and the Three Levers of Innovation for Affordable Care
- What is the Clinical Practice Research Datalink?
- Pricing Science Meets Military Science
- Lipitor and Crestor fight on price, both equally unimpressive
- Dr. Bates’ Talkback: How to profitably compete in the oncology market
- Ulf Staginnus' hard hitting and spot-on editorial: market access-what we really need is some honesty
- Market access: How network intelligence increases value
- Health Systems Evidence: Why use it and who's behind it?
- 2012 AMCP Awards Nominations
- Germany smiles on AZ's Brilique
- For Pfizer, 5,000 lawsuits resolved, 5,000 to go
- The value of industry involvement in HTA - Joint Healthcare Industry Paper
- Hysterical video on Pharma Sales Reps by Eyeforpharma. I love these guys!
- NICE rejects AstraZeneca's breast cancer drug Faslodex
- If Pharma is looking to Detroit for answers, we're in big trouble
- CDC: Health reform extends coverage to young Americans
- Podcast: Optimize the clinical - commercial transition for strategic advantage
- 2012 AMCP/FMCP/Genentech Managed Care and Customer Operations (MCCO) Summer Internship Program
- Call for Papers: Value In Health Regional Issues
- Utilizing HEOR Stategies Globally: Interview with Betsy J. Lahue, VP, HEOR at BD
- CMS Requests Comments on Coverage With Evidence Development
- The Advent of Mobile IRT Solutions in Clinical Trials
- Atlas maps out variation in NHS
- Podcast with Beckie Fenrick, Senior Director BCBS
- BlueCross Health Institute Addresses Rising Drug Costs
- ISPOR Scientific Awards accepting nominations for 4 separate awards, due by Feb. 10, 2012
- 12 Days of Pricing, Article 1: For the U.S. Post Office, One Price for All Isn’t Working Out So Wel
- One Day You’re In; The Next Day You’re Out: Dendreon’s Top Dog Voted “Worst Biotech CEO” in Poll.
- Poland: New price negotiations for RX drugs
- Lansley accused of NHS U-turn by imposing centralised targets
- International Study Assesses Disease Registries as Means for Improving Health Care Value
- Managed Care Summit Podcast
- STAY IN CONTROL OF YOUR REMS PROGRAM
- Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement
- Archimedes' Idividualized Guidelines and Outcomes (IndiGO) Platform Deployed in Colorado Beacon Con
- Andrew Lansley launches 60 NHS 'patient outcome measures'
- The Real Way to Lean Success: Suck Out the IT Fat
- The Year's Top 5 Tech Surprises
- Report shows Big Pharma's Patent Cliff in Graphic Detail
- Qualcomm unit to provide wireless solutions for devices
- Even more presentation available from ISPOR Europe
- What Managed Care Thinks Of Pfizer And Its Lipitor Strategy
- Private Market ACO's: Retool for the Industry's New Era
- Revisiting issues, drawbacks and opportunities with observational studies in comparative effectivene
- Patient Reported Outcomes Now Comprise 13% of Market Access Budgets
- CEO: Roche would consider more money-back deals
- NICE rejects Novartis MS pill despite cost cut
- Facing Generic Lipitor Rivals, Pfizer Battles to Protect Its Cash Cow
- Geographic Variation in Physicians' Responses to a Reimbursement Change
- Aetna Encourages Evidence-Based Treatment Decisions Through Education Program for Providers
- Multi-Payer Claims Database Moves Ahead
- Video: Dr. Lakdawalla CER Discussion
- Podcast: Key Challenges Payers Face in Oncology
- A Roadmap to Improved Medication Adherence
- NICE at heart of new NHS Commissioning Outcomes Framework
- White Paper Reveals Types and Locations of More Than 160 ACOs or ACO-Like Organizations
- FierceBiotech's 2011 Women in Biotech
- More Insurers are Thinking Inside the Box; Blue Shield of California Opens CA
- Survey on Pharma Wish List for Santa. Take it. Get a Laugh.
- 2011 Benchmarks in Accountable Care Organizations: Metrics from Early ACO Adopters
- AMCP 2012 Awards Nominations
- Quality of life in Italy
- Drugmakers’ Returns on Research Fall as Pipeline Projects Fail
- Pfizer Uses Coupons, PBM Deals, Possible OTC Conversion to Head Off Generic Lipitor
- JMCP Supplement on Comparative Effectiveness and Real World Data
- How to Read a Paper: The Basics of Evidence-Based Medicine Book
- Tiered Pricing Not Always a Win-Win
- HTA Methods Digest
- Beware Marketing Strategies Masquerading as Evidence Based Medicine
- Big Pharma Counts Cost of R&D Decline
- Strategic Alliance Executives
- Competition and the Reference Pricing Scheme for Pharmaceuticals
- Does price reveal poor-quality drugs? Evidence from 17 countries
- Does a German Launch Make Sense?
- 10 unusual biotech and pharma logos
- Why treating patients like customers means reimbursement dollars
- Latest drugs scarce in Wales' 'low-spend' NHS
- Value-based Pricing in Developed Countries: Past, Present, Future
- Market Failures in Price Referencing
- HTA of Med Devices in EU: Implications for Industry
- Value-baed Pricing in Practice presentations from ISPOR
- European network for HTA Joint Action between European Commission and EU Member States
- Multi-criteria decision analysis: roadmap for development.
- Greenpark Collaborative: US and Europe Perspective
- Value-Based Pricing: How do Approaches Vary by Health Care Context?
- Valuing Diagnostics: Do we need Different Metrics?
- Govt and Industry weigh in: The Reality of Real World Data And Its Use In Health Care Decisions
- The reality of real world data and its use in health care decisions in Europe
- Adrian Towse weighs in on Centralized EU Pricing/Reimbursement Pros & Cons
- ISPOR Madrid presentations available here in PPT!
- Conceptualization of Category-Oriented Likelihood Ratio
- Pfizer exec: Indian price move would push pharma to 'semi-recession'
- FDA nixes approval of Avastin for breast cancer
- Deficit Reduction Law Makes Comparative Effectiveness Research More Important Than Ever
- The supercommittee’s health spending paradox, in three charts
- NICE turns down another breast cancer drug
- Dutch initiative seeks to integrate the organization of care delivery
- CONSORT quality of life extension under development
- New NCQA Accreditation Program Identifies ACOs That Are Most Likely to Succeed
- Integrating historical clinical and finalncial data for pharmacological research
- Purdue hits health care tech milestone
- ePRISM® reveals Impressive Results for Improving PCI Informed Consent
- Penalty Premiums
- Health Technology Assessment (HTA): a European perspective
- Penn Physicians Point To Patient Narratives to Bolster the Case of Evidence-Based Medicine
- The Role of Cost-Effectiveness in U.S. Vaccination Policy
- Watch and Vote: Video from Pharma Faceoff on Pharmacy Co-Pay Cards
- Why Steve Jobs & Bill Gates could not fix the pharmaceutical industry
- China as an emerging market: drug prices are a mixed blessing due to price slashing
- What Bill Gates Says About Drug Companies
- Video: “The Joy of Stats”, a fascinating 4 minute lecture by Hans Rosling
- Scorpion antivenom's price stings AZ patients
- The IMS Institute examines the drug shortages problem from an entirely new angle
- Pfizer's Lipitor survival strategy under attack
- PCORI Request for Proposal
- Emerging Markets: Tread Carefully
- Have you optimized your Market Access Efforts?
- WP243 Thought Leader Compensation: US vs. EU
- Emerging markets: the engine of growth in the world economy
- Reasons for Medication Non-Adherence Affect Patient Outcomes
- Optum Brings Together Dedicated Team to Help Health Systems Rapidly Build and Implement Accountable
- Wennberg receives ethics award
- Biotechnology & Medical Investors Database
- Real-world evidence: HealthCore's Journey
- Implementing patient-reported outcomes assessment in clinical practice
- World's Oldest Clinical Trial...and Health Economics Not Far Behind
- Is the U.K.'s cancer-drugs fund unfair?
- REAL and Present Danger: Revealing the inside story of the medical industry...
- Utilizing Health Outcomes Data to Drive Company Decision-Making
- Therapeutic and Diagnostic Devices Outcomes Research
- Medicare Drug Prices and the Deficit
- Evidence: AstraZeneca and a new kind of science
- Patient-Centered Outcomes Research Institute Request for Proposal – Review of Guidance
- Comparative Effectiveness Research as a Drug Development Tool
- CMS Announces Accountable Care Organization Rule
- e-Book: Health Economics: An International Perspective
- Evidence-Based Medicine Powerpoint Presentation
- Communicating Product Value Clearly to a Demanding Payer Audience
- Market Access: A Viewpoint from the Field
- Assymmetry in the Ability to Communicate CER Findings
- The Patient-Centered Outcomes Research Institute Resource Guide
- Russia: Needs to Invest in Cold Chain Infrastructure for Biopharma to Grow
- Health Outcomes Worldwide Secures Financing
- New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
- Parexel Expands commercialization services
- PAS reverses NICE rejection of Takeda
- MGMA Urges Practices To Take Charge
- 5 Threats To Value-Based Insurance Design
- Pfizer Establishes Precision Medicine Research Collaboration With Medco
- Pharm Exec: 30 Years, 30 Leaders
- Quintiles Acquires Outcome Sciences, Inc., Premier Observational Research Company
- Medical Societies: Exclude Cost Analysis from Outcomes Research
- Can a Static Threshold Acommodate the Dynamics of Drug Development?
- Career Path a Top Concern for Health Outcomes Liaisons
- Pay for performance contracts for Avastin in Germany
- Health economists offer new decision framework for NICE
- Choosing the Right Health-Care Plan
- Abbott spin-off could attract mega merger
- Four Ways Women Stunt Their Careers Unintentionally
- Abbott Plans to Split Into Two Companies, finalized by end of 2012
- Eli Lilly's profits fall 5% in Q3
- Data sharing key in CIGNA collaborative accountable care
- Insurer Pumps $20 Million Into Accountable Care Tech
- Pfizer buying patient's personal info from Australian pharmacists.
- Off-Label Changes Coming? Sorrell Ruling Prompts New Legal Challenges
- IOM Urges Affordable Essential Benefits Package
- Op-Ed: Comparative Effectiveness Reviews Mean Fewer Cures
- Query Health at the HIT Policy Committee Meeting
- Medco CEO Champions Robots Over Pharmacists
- Many Pills, Many Not Taken
- Anthem pays patients to choose cheaper docs
Spotlight of the Week
Conference Of The Week
DIA 2012: Collaborate to Innovate
48th Annual Meeting
June 24- 28, 2012, Pennsylvania Convention Center, Philadelphia
Reserve "Conference of the Week". Contact us.
Job Of The Week
Associate Director, GHEOR CV/MET
Bristol-Myers Squibb, Princeton, New Jersey
Reserve "Job of the Week". Contact us.
Link Of The Week
Need some help crafting your CV so that it isn’t DOA? Do you know the HEOR Job Outlook for 2012? Visit HealthEconomics.Com Job Search Tips. If you are a hiring manager or a recruiter and would like to contribute, contact us.
Reserve "Link of the Week". Contact us.
Survey Of The Week
John Mack (@pharmaguy), our Favorite Pharma Marketing Commentator and Trend-Analyzer, is running a survey on pharma’s use of celebrities as spokespeople and whether they should disclose compensation details. Participate, and you’ll get a copy of the results to date at the end of the short survey.
Reserve "Survey of the Week". Contact us.
Partners
